Although patients possessing baseline AFP ≥ 400 ng/ml exhibited a markedly shorter median OS and PFS (8.1 and 3.7 months, respectively) compared with their counterparts (15.7 and 4.6 months, respectively), the survival outcome appeared to be comparable with those observed in the phase III REACH‐2 trial (median OS, 8.5 months; median PFS, 2.8 months), which incorporated 197 HCC patients who had AFP levels of 400 ng/ml or higher and received ramucirumab after sorafenib failure.11 The gene discussed is AFP; the disease is hepatocellular carcinoma.